Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2025
Cyto - Histodiagnostiek from Antwerpen, company number BE0427146230, closed financial year 2025 with a result of € -13,179 after tax. For that financial year Cyto - Histodiagnostiek recorded a gross margin of € 96,889 and equity of € -319,943. Compared with financial year 2024, the result moved from € 0 to € -13,179. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ -319,943
▼ € 13,179 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13,179
▼ still € 0 profit in 2024
Profit after tax over the fiscal year.
€ 52
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -338,535.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 373,350
▲ 4% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -343 | € 0 | - | € 96,889 | |
| Profit after taxes | € 112,712 | € 0 | € 0 | € -13,179 | |
| Equity | € -306,763 | € -306,763 | € -306,763 | € -319,943 | ▼ € 13,179 |
| Total debts | € 368,801 | € 368,801 | € 368,801 | € 381,981 | ▲ 4% |
| Cash | € 52 | € 52 | € 52 | € 52 | |
| Retained profit | € -325,355 | € -325,355 | € -325,355 | € -338,535 | ▼ € 13,179 |
| Balance sheet total | € 62,038 | € 62,038 | € 62,038 | € 62,038 |
Key figures of Cyto - Histodiagnostiek, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Cyto - Histodiagnostiek?
What happened at Cyto - Histodiagnostiek in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Cyto - Histodiagnostiek is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- New annual accounts for financial year 2025: loss of € 13,179. Source: NBB ↗
- Thomas Debaene became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 112,712 profit in 2022 to € 13,179 loss in 2025.
Best year ever: 2022, with € 112,712 profit.
A new publication or filing at Cyto - Histodiagnostiek? We notify you, reason included.
Follow Cyto - HistodiagnostiekDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Cyto - Histodiagnostiek is Thomas Debaene. Thomas Debaene is also behind ERGOLINE and Marreal Invest.
Directors
According to the 2025 annual accounts
since 2025
Establishments
Establishment units
Physical locations of this company
Koninklijkelaan 60
2600 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →BERSCHADER INTERNATIONAL
€ -1,282 gross margin · 2025
EPODICHT BEHEER
€ -59,766 gross margin · 2025
EUROPEAN RENEWABLE ENERGY COUNCIL
HOLBERG
€ -688 gross margin · 2025
DE KONINKLIJKE 60
€ 45,226 gross margin · 2025
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Website info
Features
Security
Network
Details
- Company number
- 0427.146.230
- VAT number
- BE 0427.146.230
- Registered office
- Koninklijkelaan 60, 2600 Antwerpen
- Names & denominations
- Cyto - Histodiagnostiek
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 7 September 1984
- Peppol
- Not registered
- Contact
- anteius.be